Advanced Clinical Software to Showcase StudyManager Sponsor Edition at Partnerships with CROs Conference

SEATTLE - Advanced Clinical Software, Inc. will showcase its new clinical trial management solution, StudyManager SE, at this year’s 11th Annual EDC & Beyond conference in Orlando, FL. StudyManager SE is designed for clinical trial sponsors, including pharmaceutical companies, medical device companies, BioTechs, and contract research organizations. It complements the world’s most widely used suite of clinical trial management products for research providers, which includes StudyManager CTMS, EDC, and IRB.

StudyManager SE is significant because it fills an overlooked niche in the industry by offering middle-tier research sponsors and CROs an affordable, robust trial management platform. By providing clinical data collection, study management, and real-time interaction among study administrators, study monitors, and site users in one package, StudyManager SE will improve overall performance by expediting operations and reducing costs.

Historically, many of the benefits offered by StudyManager SE were limited to top-tier pharmaceutical companies and CROs having the resources to purchase high-priced CTMS and EDC programs. In creating StudyManager SE, ACS has substantially lowered the price point, enabling many more organizations that conduct clinical research to achieve greater success. The product announcement is also a strategic move by ACS into the sponsor side of research after having established itself as the dominant player among research providers such as health systems, academic medical centers and research sites.

“We specifically set out to design a study management solution for middle-tier CROs and sponsors that typically can’t engage the big vendors,” stated Bruce Schatzman, President and CEO of ACS. “We recognized that this was an under-served group, and we wanted to create a solution that would bridge the gap both functionally and financially.” He also noted, “This is an important step for ACS because it is our first venture into offering a sponsor-side product after spending the last decade establishing ourselves on the provider side of clinical research.”